Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:UBX

UNITY Biotechnology (UBX) Stock Price, News & Analysis

UNITY Biotechnology logo

About UNITY Biotechnology Stock (NASDAQ:UBX)

Key Stats

Today's Range
$0.20
$0.32
50-Day Range
$0.18
$0.88
52-Week Range
$0.20
$3.10
Volume
3.73 million shs
Average Volume
284,137 shs
Market Capitalization
$3.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.33
Consensus Rating
Hold

Company Overview

UNITY Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

UBX MarketRank™: 

UNITY Biotechnology scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    UNITY Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Upside Potential

    UNITY Biotechnology has a consensus price target of $2.33, representing about 1,203.5% upside from its current price of $0.18.

  • Amount of Analyst Coverage

    UNITY Biotechnology has received no research coverage in the past 90 days.

  • Read more about UNITY Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for UNITY Biotechnology are expected to grow in the coming year, from ($1.45) to ($1.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    UNITY Biotechnology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for UBX.
  • Dividend Yield

    UNITY Biotechnology does not currently pay a dividend.

  • Dividend Growth

    UNITY Biotechnology does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for UBX.
    • Insider Buying vs. Insider Selling

      In the past three months, UNITY Biotechnology insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 5.80% of the stock of UNITY Biotechnology is held by insiders.

    • Percentage Held by Institutions

      Only 29.49% of the stock of UNITY Biotechnology is held by institutions.

    • Read more about UNITY Biotechnology's insider trading history.
    Receive UBX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for UNITY Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    UBX Stock News Headlines

    Another gold high? Here’s the move Wall Street is missing …
    Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says the real opportunity is in a little-known strategy that has historically outpaced gold’s rallies many times over — including one past run where investors saw gains of more than 26,000%.tc pixel
    UBX Unity Biotechnology, Inc. - Seeking Alpha
    See More Headlines

    UBX Stock Analysis - Frequently Asked Questions

    UNITY Biotechnology, Inc. (NASDAQ:UBX) issued its earnings results on Tuesday, April, 22nd. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43).

    UNITY Biotechnology's stock reverse split on the morning of Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

    UNITY Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

    Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK).

    Company Calendar

    Last Earnings
    4/22/2025
    Today
    10/04/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:UBX
    CIK
    1463361
    Fax
    N/A
    Employees
    60
    Year Founded
    2009

    Price Target and Rating

    High Price Target
    $4.00
    Low Price Target
    $1.00
    Potential Upside/Downside
    +1,203.5%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.33
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($1.62)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$25.99 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -246.82%
    Return on Assets
    -58.81%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    1.95
    Quick Ratio
    1.95

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.39 per share
    Price / Book
    0.46

    Miscellaneous

    Outstanding Shares
    17,212,000
    Free Float
    16,214,000
    Market Cap
    $3.08 million
    Optionable
    Optionable
    Beta
    0.92

    Social Links

    These 7 Stocks Will Be Magnificent in 2025 Cover

    Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

    Get This Free Report

    This page (NASDAQ:UBX) was last updated on 10/4/2025 by MarketBeat.com Staff
    From Our Partners